All studies are driven by patient’s safety as a priority. With over 30,000 patients recruited into our projects since 2005, we place high importance on introducing patient centricity principles into every stage of a trial.  
With that in mind, OCT pharmacovigilance team covers a range of safety monitoring and safety reporting tasks and responsibilities in the course of a study.

Alt

Drug development is a costly and time-consuming process. Therefore, it is vital to obtain all-encompassing information on drug safety to ensure its speedy marketing authorization and prevention of unfavorable outcomes.

Ekaterina Andrianova Safety Manager, MD, PhD

We guarantee that all safety information is collected and reported to investigators and appropriate regulatory authorities within the required timelines.


We ensure safety reporting of your study:
• Set up of PVG specific processes and procedures
• Collection, description and processing of serious adverse events data
• Evaluation of safety data
• Data entry and MedDRA coding
• Medical review, quality control
• Reporting to regulatory authorities and investigator sites about presumed  serious and unforeseen adverse reactions (SUSAR)
• Preparation and submission of annual safety reports to regulatory authorities and investigator sites


Thanks to the experience of our specialists in the field of pharmacovigilance and their regulatory expertise, we prepare high quality safety reports within the required timelines.